Future of coagulation factor replacement therapy
Authors:
- F. PeyvandiFPF. Peyvandi
- I. GaragiolaIGI. Garagiola
- S. SeregniSSS. Seregni
- 1 June 2013
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 11, 84-98
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 73 references indexed in Scilit:
- A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice modelsBlood, 2013
- Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion proteinJournal of Thrombosis and Haemostasis, 2013
- Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patientsBlood, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Phase I, randomized, double‐blind, placebo‐controlled, single‐dose escalation study of the recombinant factor VIIa variant BAY 86‐6150 in hemophiliaJournal of Thrombosis and Haemostasis, 2012
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood, 2012
- Nanoparticle-based targeted drug deliveryExperimental and Molecular Pathology, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Strategies to improve plasma half life time of peptide and protein drugsAmino Acids, 2006
- Design and operation of a recombinant mammalian cell manufacturing process for rFVIIIAnnals of Hematology, 1994